First Pill for Rare Lung Disease Lands $475M Deal

Imagine spending every single week of your adult life sitting in an infusion center, hooked to an IV for an hour, just to slow down a disease destroying your lungs. That's been reality for tens of thousands of Americans with alpha-1 antitrypsin deficiency since 1987.

On August 11, 2026, that four-decade routine moved closer to ending. London-based Mereo BioPharma and California's Sentynl Therapeutics announced a $475 million deal to bring alvelestat to market: the first pill designed to treat this rare genetic lung disease.

Alpha-1 antitrypsin deficiency happens when a genetic mutation stops the liver from making enough of a protective protein. Without it, an inflammatory enzyme called neutrophil elastase attacks the lungs unchecked, destroying the tiny air sacs that transfer oxygen into the blood. Patients develop severe emphysema, often starting in their 30s and 40s.

The current treatment replaces the missing protein through weekly infusions of material purified from donated blood plasma. It costs over $200,000 per year, requires clinic visits, and only slows the damage. Worse, protein levels drop below protective thresholds in the days before each infusion, leaving a gap when the enzyme can still attack.

Alvelestat works differently. Instead of replacing the missing protein, it directly blocks the destructive enzyme. As a small synthetic molecule, it reaches parts of lung tissue that infused proteins can't penetrate, and twice-daily pills keep enzyme activity suppressed around the clock.

Two Phase 2 clinical trials tested 161 patients across North America and Europe. The results showed alvelestat blocked more than 90% of neutrophil elastase activity. Patients tolerated the treatment well, with side effects no worse than placebo.

The $475 million deal gives Sentynl exclusive US commercialization rights while Mereo leads the global Phase 3 trials needed for FDA approval. Mereo's stock jumped 40% on the news.

Why This Inspires

Between 50,000 and 80,000 Americans carry the most severe form of this disease. For them, this isn't just about convenience, though swapping weekly clinic trips for pills taken at home matters enormously. It's about continuous protection their lungs have never had before.

The pill can't reverse lung damage that's already happened, but it can stop new destruction in its tracks. Combined with earlier diagnosis, that means younger patients might preserve lung function for decades longer than their parents' generation could.

After 40 years of essentially unchanged treatment, a genetic lung disease is finally getting an innovation that puts daily life back in patients' hands.